BlueMountain Capital Management LLC increased its position in Chemed Co. (NYSE:CHE) by 30.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,546 shares of the company’s stock after buying an additional 827 shares during the quarter. BlueMountain Capital Management LLC’s holdings in Chemed were worth $1,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Chemed during the 1st quarter worth approximately $390,000. Prudential Financial Inc. lifted its holdings in shares of Chemed by 10.5% in the 1st quarter. Prudential Financial Inc. now owns 66,091 shares of the company’s stock worth $18,034,000 after purchasing an additional 6,307 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Chemed by 2.2% in the 1st quarter. Swiss National Bank now owns 27,800 shares of the company’s stock worth $7,586,000 after purchasing an additional 600 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Chemed by 7.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 116,793 shares of the company’s stock worth $31,869,000 after purchasing an additional 7,659 shares in the last quarter. Finally, Aperio Group LLC lifted its holdings in shares of Chemed by 1.4% in the 1st quarter. Aperio Group LLC now owns 15,477 shares of the company’s stock worth $4,223,000 after purchasing an additional 221 shares in the last quarter. 90.55% of the stock is owned by institutional investors.
Shares of CHE opened at $318.47 on Friday. Chemed Co. has a 12-month low of $186.09 and a 12-month high of $335.99. The company has a current ratio of 1.04, a quick ratio of 1.01 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $5.06 billion, a P/E ratio of 59.42, a PEG ratio of 2.85 and a beta of 1.15.
Chemed (NYSE:CHE) last issued its earnings results on Wednesday, July 25th. The company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. Chemed had a return on equity of 33.57% and a net margin of 11.00%. The company had revenue of $441.80 million for the quarter, compared to analysts’ expectations of $434.28 million. During the same period last year, the business earned $2.15 EPS. Chemed’s quarterly revenue was up 6.4% compared to the same quarter last year. sell-side analysts forecast that Chemed Co. will post 11.05 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 31st. Shareholders of record on Monday, August 13th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Friday, August 10th. This is a boost from Chemed’s previous quarterly dividend of $0.28. This represents a $1.20 annualized dividend and a yield of 0.38%. Chemed’s dividend payout ratio (DPR) is 22.39%.
In other Chemed news, Director Donald E. Saunders sold 300 shares of the firm’s stock in a transaction on Monday, August 20th. The stock was sold at an average price of $319.22, for a total transaction of $95,766.00. Following the transaction, the director now directly owns 8,701 shares in the company, valued at approximately $2,777,533.22. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Patrick P. Grace sold 250 shares of the firm’s stock in a transaction on Friday, June 22nd. The shares were sold at an average price of $323.76, for a total value of $80,940.00. Following the transaction, the director now owns 4,520 shares in the company, valued at $1,463,395.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 25,256 shares of company stock worth $8,127,168. Company insiders own 4.90% of the company’s stock.
A number of equities analysts recently issued reports on CHE shares. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $350.00 target price on the stock in a report on Tuesday, July 31st. Royal Bank of Canada increased their target price on Chemed to $321.00 and gave the stock a “market perform” rating in a report on Monday, July 30th. Finally, ValuEngine cut Chemed from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $315.33.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Recommended Story: Asset Allocation and Your Retirement
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.